Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

Clinical Gastroenterology and Hepatology

Volumn 17, Issue 4, 2019, Pages 748-755.e3

  Younossi, Zobair ^a   Stepanova, Maria ^b   Ong, Janus P ^c   Jacobson, Ira M ^d   Bugianesi, Elisabetta ^e   Duseja, Ajay ^f   Eguchi, Yuichiro ^g   Wong, Vincent W ^h   Negro, Francesco ⁱ   Yilmaz, Yusuf ^j   Romero Gomez, Manuel ^k   George, Jacob ^l   Ahmed, Aijaz ^m   Wong, Robert ⁿ   Younossi, Issah ^b   Ziayee, Mariam ^b   Afendy, Arian ^b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^g SAGA UNIVERSITY HOSPITAL   (Japan)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ UNIVERSITY OF GENEVA   (Switzerland)

^j MARMARA UNIVERSITY   (Turkey)

^k HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^l WESTMEAD HOSPITAL   (Australia)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ Alameda Health System   (United States)

more..

Author keywords

Liver Cancer; Mortality; NAFLD; OPTN; Transplant Waitlist; UNOS

Indexed keywords

ADULT; AGE DISTRIBUTION; ALCOHOL LIVER DISEASE; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BLACK PERSON; BLEEDING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DETERIORATION; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEPATIC ENCEPHALOPATHY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY RISK; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT DROPOUT; POSTOPERATIVE COMPLICATION; PREVALENCE; RESPIRATORY FAILURE; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SURGICAL MORTALITY; SURGICAL RISK; TREND STUDY; UNITED STATES; VARICEAL BLEEDING; ADOLESCENT; AGED; ALCOHOL LIVER CIRRHOSIS; COHORT ANALYSIS; COMPLICATION; LIVER TUMOR; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 85059571956     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.05.057     Document Type: Article

References (33)

1. Wong, R.J., Aguilar, M., Cheung, R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
2. Goldberg, D., Ditah, I.C., Saeian, K., et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 152 (2017), 1090–1099.e1.
3. Younossi, Z.M., Stepanova, M., Rafiq, N., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53 (2011), 1874–1882.
4. Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. Global epidemiology of nonalcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
5. Golabi, P., Fukui, N., de Avila, L., et al. The global epidemiology of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Hepatology 66:Suppl (2017), 1177A–1178A.
6. Kwok, R., Choi, K.C., Wong, G.L., et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65 (2016), 1359–1368.
7. Stepanova, M., Rafiq, N., Makhlouf, H., et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 58 (2013), 3017–3023.
8. Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
9. Golabi, P., Otgonsuren, M., de Avila, L., et al. Components of metabolic syndrome increase the risk of mortality in non-alcoholic fatty liver disease (NAFLD). Medicine (Baltimore), 97, 2018 e0214.
10. Massarweh, N.N., El-Serag, H.B., Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control 24 (2017), 1–11.
11. Younossi, Z.M., Otgonsuren, M., Henry, L., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
12. Kim, G.A., Lee, H.C., Choe, J., et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol 68 (2018), 140–146.
13. Dyson, J., Jaques, B., Chattopadyhay, D., et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 60 (2014), 110–117.
14. Pais, R., Fartoux, L., Goumard, C., et al. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 46 (2017), 856–863.
15. Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59 (2014), 2188–2195.
16. Cholankeril, G., Wong, R.J., Hu, M., et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci 62 (2017), 2915–2922.
17. Parikh, N.D., Marrero, W.J., Wang, J., et al. Projected increase in obesity and non-alcoholic steatohepatitis-related liver transplantation waitlist additions in the United States. Hepatology, 2017 Epub ahead of print.
18. Cholankeril, G., Yoo, E.R., Perumpail, R.B., et al. Rising rates of hepatocellular carcinoma leading to liver transplantation in baby boomer generation with chronic hepatitis C, alcohol liver disease, and nonalcoholic steatohepatitis-related liver disease. Diseases, 5, 2017, 4.
19. Flemming, J.A., Kim, W.R., Brosgart, C.L., et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 65 (2017), 804–812.
20. Doycheva, I., Issa, D., Watt, K.D., et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in young adults in the United States. J Clin Gastroenterol 52 (2018), 339–346.
21. Younossi, Z.M., Loomba, R., Rinella, M.E., et al. Current and future therapeutic regimens for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Hepatology 68 (2018), 361–371.
22. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67 (2018), 328–357.
23. Younossi, Z., Anstee, Q.M., Marietti, M., et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15 (2018), 11–20.
24. Thuluvath, P.J., Kantsevoy, S., Thuluvath, A.J., et al. Is cryptogenic cirrhosis different from NASH cirrhosis?. J Hepatol 68 (2018), 519–525.
25. Ong, J., Younossi, Z.M., Reddy, V., et al. Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease. Liver Transpl 7 (2001), 797–801.
26. Yalamanchili, K., Saadeh, S., Klintmalm, G.B., et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 16 (2010), 431–439.
27. Younossi, Z.M., Stepanova, M., Locklear, C.T., et al. Liver transplantation (LT) for cryptogenic cirrhosis (CC) and non-alcoholic steatohepatitis (NASH) cirrhosis: twenty-two years data from the Scientific Registry of Transplant Recipients (SRTR). Hepatology 66:Suppl (2017), 899A–900A.
28. Caldwell, S., Marchesini, G., Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name. J Hepatol 68 (2018), 391–392.
29. El-Serag, H.B., Kanwal, F., Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go?. Hepatology 60 (2014), 1767–1775.
30. Davila, J.A., Morgan, R.O., Shaib, Y., et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54 (2005), 533–539.
31. Kim, S.Y., An, J., Lim, Y.S., et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol 3 (2017), 456–463.
32. Bertot, L.C., Jeffrey, G.P., Wallace, M., et al. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun 1 (2017), 53–60.
33. Sorensen, H.T., Mellemkjaer, L., Jepsen, P., et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 36 (2003), 356–359.